InvestLog
ANTX AN2 Therapeutics, Inc. logo

ANTX AN2 Therapeutics, Inc.

Healthcare
$4.85-0.82%ClosedMarket Cap: $132.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.02

P/S

0.00

EV/EBITDA

-2.17

DCF Value

$0.59

FCF Yield

-23.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-52.3%

ROA

-39.5%

ROIC

-45.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-10.0M$—
Q4 null$0.00$-8.7M$—
FY null$0.00$-35.2M$—
Q3 null$0.00$-9.4M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$9.00 - $9.00

0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Leerink PartnersOutperform
2026-05-14

Trading Activity

Insider Trades

View All
Martin Patricia A.director
SellFri Apr 10
Marks Gilbert Lynndirector
SellFri Apr 10
Aziz Kabeerdirector
SellFri Apr 10
Day Lucyofficer: Chief Financial Officer
SellMon Mar 23
Day Lucyofficer: Chief Financial Officer
SellMon Mar 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

-0.96

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Peers

BOLD logoBOLDIBIO logoIBIOINTS logoINTSITRM logoITRMNXTC logoNXTCPLUR logoPLURPSTV logoPSTVQTTB logoQTTBSABS logoSABSVRCA logoVRCA